Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of TQH2722 in healthy adults
NCT05409326Phase 1Unknown
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TQH2722 in atopic dermatitis (AD) (3 arms), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Adverse Events up to 99 days and Serious Adverse Events up to 99 days. Status: unknown.
02
Drugs
TQH2722
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05409326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05409326.